Search Within

Alison Michele Schram

Formats
  1. Journal Article (60)
  2. Meeting Abstract (59)
  3. Editorial (3)
  4. Review (3)
  5. Miscellaneous (2)
  6. Research Letter (1)
Groups
  1. Department of Medicine (128)
  2. Early Drug Development Service (128)
  3. Gynecologic Medicine Service (128)
  4. Hematology-Oncology Fellows (128)
  5. Solid Tumor Oncology Division (128)
  6. GSK Faculty (54)

More Groups

People
  1. David Hyman (49)
  2. Alexander Drilon (46)
  3. Michael Berger (24)
  4. Barry Taylor (16)
  5. Marc Ladanyi (16)
  6. Helen Won (14)

More People

Years
  1. 2025 (10)
  2. 2024 (18)
  3. 2023 (9)
  4. 2022 (16)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Annals of Oncology (13)
  3. Cancer Research (13)
  4. Cancer Discovery (9)
  5. JCO Precision Oncology (6)
  6. Clinical Cancer Research (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (36)
  2. American Association for Cancer Research (30)
  3. Oxford University Press (14)
  4. Nature Publishing Group (12)
  5. Elsevier Inc. (8)
  6. American Medical Association (3)

More Publishers

Results (128)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Basket trials: Past, present, and future
    Review

    Murciano-Goroff, Y. R.; Uppal, M.; Chen, M.; Harada, G.; Schram, A. M.
    Annual Review of Cancer Biology (2024)

    Fulltext@MSK | Save
  • The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
    Journal Article

    Kim, D. W.; Schram, A. M.; Hollebecque, A.; Nishino, K.; Macarulla, T.; Rha, S. Y.; Duruisseaux, M.; Liu, S. V.; Al Hallak, M. N.; Umemoto, K.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Defining a space for NRG1 fusion-positive tumors in lung and GI cancers
    Miscellaneous

    Spira, A. I.; Macarulla, T.; Neuzillet, C.; Sabari, J. K.; Schram, A.; Van Cutsem, E.
    Oncology (Norwalk) (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy
    Journal Article

    Walmsley, C. S.; Jonsson, P.; Cheng, M. L.; McBride, S.; Kaeser, C.; Vargas, H. A.; Laudone, V.; Taylor, B. S.; Kappagantula, R.; Baez, P.; more...
    npj Precision Oncology (2024)

    Fulltext@MSK | Save
  • Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia
    Journal Article

    Varkaris, A.; Pazolli, E.; Gunaydin, H.; Wang, Q.; Pierce, L.; Boezio, A. A.; Bulku, A.; DiPietro, L.; Fridrich, C.; Frost, A.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Defining a space for NRG1 fusion–Positive tumors in lung and GI cancers
    Editorial

    Spira, A. I.; Macarulla, T.; Neuzillet, C.; Sabari, J. K.; Schram, A.; Van Cutsem, E.
    Oncology (Norwalk) (2024)

    Fulltext@MSK | Save
  • A phase I dose-escalation study of LY3405105, a covalent inhibitor of cyclin-dependent kinase 7, administered to patients with advanced solid tumors
    Journal Article

    Garralda, E.; Schram, A. M.; Bedard, P. L.; Schwartz, G. K.; Yuen, E.; McNeely, S. C.; Ribeiro, S.; Cunningham, J.; Wang, Y.; Urunuela, A.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
    Journal Article

    Subbiah, V.; Sahai, V.; Maglic, D.; Bruderek, K.; Touré, B. B.; Zhao, S. P.; Valverde, R.; O'Hearn, P. J.; Moustakas, D. T.; Schönherr, H.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Impact of PARP inhibitor and platinum therapy on clonal hematopoiesis
    Meeting Abstract

    Baeten, J. T.; Chan, I. C. C.; Moukarzel, L.; Carter, A. C.; Patel, M.; Stopsack, K. H.; Pharoah, P.; Brenton, J.; Li, B. T.; Abida, W.; more...
    Blood (2023)

    Fulltext@MSK | Save